B7-H4 is a prognostic biomarker for poor survival in patients with pancreatic cancer

Shen, Lingwei; Qian, Yun; Wu, Weigen; Weng, Tian-Hao; Wang, Frederick X.C.; Hong, Bo; Wu, Zhigang; Wang, Qi; Sang, Yiwen; Zhang, Hong; Zhou, Xinhui; Yao, Hang‐Ping

doi:10.1016/j.humpath.2017.05.023

Cited by 29 publications

(21 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Manual review of the reference lists of retrieved manuscripts concerning B7H1 or B7H4 expression in pancreatic cancer yielded four additional studies that met the inclusion criteria for this meta-analysis. However, 16 studies [16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31] were finally selected for metaanalysis after the removal of duplicates and the application of eligibility criteria.…”

Section: Methodsmentioning

confidence: 99%

The prognostic value of B7H1 and B7H4 expression in pancreatic cancer: A meta-analysis

Chen

et al. 2019

Int J Biol Markers

View full text Add to dashboard Cite

Objective: The clinical implications of B7H1 and B7H4 in pancreatic cancer have been described however, the prognostic significance of these genes in pancreatic cancer patients remains inconclusive. The aim of the present study was to evaluate the prognostic role of B7H1 and B7H4 in pancreatic cancer patients. Methods: Electronic databases (PubMed, EMBASE, and the Cochrane Library) were searched for relevant articles published before May 2019. Meta-analyses were performed by pooling the hazard ratios (HRs) between overall survival or cancer-specific survival and high or low expression of B7H1/B7H4 in pancreatic cancer patients. Subgroup and sensitivity analyses were performed, and sources of variabilities were explored by performing meta-regression. Results: Sixteen studies (1434 patients’ data) were included. Compared with low expression, high expression of B7H1 was associated with significantly poor overall survival (HR 1.92 (95% confidence interval (CI) 1.35, 2.74); P<0.001) and cancer-specific survival (HR 2.46 (95% CI 1.55, 3.90); P<0.001). High expression of B7H4 also predicted poor overall survival (HR 2.38 (95% CI 1.89, 3.00); P<0.001). In subgroup analyses, a significant association between B7H1 and overall survival was observed for trials conducted in China (HR 2.08 (95% CI 1.29, 3.34)) but not in Japan (HR 1.98 (95% CI 1.33, 2.96)); or in studies with <50% patients having high expression (HR 2.02 (95% CI 1.40, 2.91)) but not in studies with >50% patients with high expression (HR 1.40 (95% CI 0.87, 2.26)). Conclusion: The current study suggests that high B7H1 and B7H4 expression is associated with a poor prognosis in pancreatic cancer patients.

show abstract

Section: Methodsmentioning

confidence: 99%

The prognostic value of B7H1 and B7H4 expression in pancreatic cancer: A meta-analysis

Chen

et al. 2019

Int J Biol Markers

View full text Add to dashboard Cite

show abstract

“…Then, 10 studies that met the exclusion criteria were removed after full text review. Finally, 6 eligible studies [ 14 – 19 ] were enrolled for meta-analysis. Table 1 provided the basic and summarized characteristics of the enrolled studies.…”

Section: Resultsmentioning

confidence: 99%

“…The HRs for OS were available in 5 studies [ 14 – 18 ] involving 375 patients. As the heterogeneity among studies was not significant ( I 2 = 3.05; Ph = 0.550), the fixed-effects model was utilized (Fig.…”

Section: Resultsmentioning

confidence: 99%

The prognostic value of B7-H4 in pancreatic cancer

Chen

Luan²,

Yuan³

et al. 2018

Medicine

View full text Add to dashboard Cite

Background:There were many reports suggesting that different kinds of tumors can express B7-H4; however, the prognostic value in cancer was still unclearly. Therefore, we conducted a meta-analysis to investigate the relationship between overexpression of B7-H4 with the prognostic value in pancreatic cancer patients.Materials and Methods:The Pubmed, Embase, Cochrane Library, Ovid, Web of Science, and Chinese research database (including CBM, CNKI, and WAN FANG) were searched for related literature published until October 12, 2017. The pooled odds ratios (ORs) and/or pooled hazard ratios (HRs) for clinical pathological factors and overall survival (OS) were calculated and analyzed using Stata software. To assess whether an individual study had an impact on the result, sensitivity analysis was performed for all included individual studies using the fixed-effects model. Publication bias was evaluated using Egger's and Begg's tests.Results:Data from 6 observational studies including 442 patients were summarized in this meta-analysis, and each study was eligible for inclusion based on included and exclude criteria. The pooled results indicated that the B7-H4 overexpression could predict the presentation of lymph node metastasis (OR = 3.94, 95% CI: 1.22–12.66, P = .022), advanced TNM stage (T = the extent of the primary tumor, N = regional lymph nodes, M = distant metastases) (III+IV vs I+II; OR = 7.63, 95% CI: 2.46–23.66, P < .001), and the poor OS (HR = 3.00, 95%CI = 2.20–4.10, P < .001) in PC patients.Conclusions:This study reveals that high expression of B7-H4 is an unfavorable prognostic factor for patients with pancreatic cancer. These results may guide the clinical management of this patient population.

show abstract

“…B7‐H4 regulates T‐cell activation and inhibition by interacting with ligands on surface receptors and has been shown to contribute to tumor growth by blocking T‐cell‐mediated immune surveillance . B7‐H4 is also expressed in many subtypes of cancers, including endometrial, ovarian, lung, breast, esophagus, and pancreatic cancer, as shown in Fig. d,e.…”

Section: Emerging Prognostic Biomarkersmentioning

confidence: 97%

Overview of established and emerging immunohistochemical biomarkers and their role in correlative studies in MRI

Alvi

Gupta

Borok

et al. 2019

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Clinical practice in radiology and pathology requires professional expertise and many years of training to visually evaluate and interpret abnormal phenotypic features in medical images and tissue sections to generate diagnoses that guide patient management and treatment. Recent advances in digital image analysis methods and machine learning have led to significant interest in extracting additional information from medical and digital whole‐slide images in radiology and pathology, respectively. This has led to significant interest and research in radiomics and pathomics to correlate phenotypic features of disease with image analytics in order to identify image‐based biomarkers. The expanding role of big data in radiology and pathology parallels the development and role of immunohistochemistry (IHC) in the daily practice of pathology. IHC methods were initially developed to provide additional information to help classify tumors and then transformed into an indispensable tool to guide treatment in many types of cancer. IHC markers are used in daily practice to identify specific types of cells and highlight their distributions in tissues in order to distinguish benign from neoplastic cells, determine tumor origin, subclassify neoplasms, and support and confirm diagnoses. In this regard, radiomics, pathomics, and IHC methods are very similar since they enable the extraction of image‐based features to characterize various properties of diseases. Due to the dramatic advancements in recent radiomics research, we provide a brief overview of the role of established and emerging IHC biomarkers in various tumor types that have been correlated with radiologic biomarkers to improve diagnostic accuracy, predict prognosis, guide patient management, and select treatment strategies. Level of Evidence: 5 Technical Efficacy: Stage 3 J. Magn. Reson. Imaging 2020;51:341–354.

show abstract

B7-H4 is a prognostic biomarker for poor survival in patients with pancreatic cancer

Cited by 29 publications

References 37 publications

The prognostic value of B7H1 and B7H4 expression in pancreatic cancer: A meta-analysis

The prognostic value of B7H1 and B7H4 expression in pancreatic cancer: A meta-analysis

The prognostic value of B7-H4 in pancreatic cancer

Overview of established and emerging immunohistochemical biomarkers and their role in correlative studies in MRI

Contact Info

Product

Resources

About